How does EMD's PS Ratio compare to its peers?

EMD is expensive based on its Price-To-Sales Ratio (7.4x) compared to the peer average (2.9x).

How does EMD's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

EMD is expensive based on its Price-To-Sales Ratio (7.4x) compared to the Australian Pharmaceuticals industry average (4.9x).

What is EMD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate EMD's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of EMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate EMD's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Emyria (CHIA:EMD) - Stock Price, News & Analysis

EMD Stock Overview

Engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. More details

EMD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Earnings have declined by 22.7% per year over past 5 years

Highly volatile share price over the past 3 months compared to the Australian market

Does not have a meaningful market cap (A$16M)

Does not have meaningful revenue (A$2M)

+ 1 more risk

Emyria Limited Competitors

Ecofibre

ASX:EOF

AU$15.4m

Invion

ASX:IVX

AU$14.3m

Nyrada

ASX:NYR

AU$21.0m

Althea Group Holdings

ASX:AGH

AU$19.3m

Price History & Performance

Summary of all time highs, changes and price drops for Emyria
Historical stock prices
Current Share Price	AU$0.04
52 Week High	AU$0.077
52 Week Low	AU$0.027
Beta	0.81
11 Month Change	33.33%
3 Month Change	21.21%
1 Year Change	-47.37%
33 Year Change	-91.92%
5 Year Change	n/a
Change since IPO	-72.41%

Recent updates

Shareholder Returns

	EMD	AU Pharmaceuticals	AU Market
7D	17.6%	-16.4%	0.9%
1Y	-47.4%	32.3%	18.4%

Return vs Industry: EMD underperformed the Australian Pharmaceuticals industry which returned 32.3% over the past year.

Return vs Market: EMD underperformed the Australian Market which returned 18.4% over the past year.

Price Volatility

Is EMD's price volatile compared to industry and market?
EMD volatility
EMD Average Weekly Movement	17.6%
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.2%

Stable Share Price: EMD's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: EMD's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

Founded	Employees	CEO	Website
2018	n/a	Michael Winlo	emyria.com

Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson’s disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications. The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is under preclinical trial program; and provides psychological trauma care facility under the Pax Centre name.

Emyria Limited Fundamentals Summary

How do Emyria's earnings and revenue compare to its market cap?
EMD fundamental statistics
Market cap	AU$16.20m
Earnings (TTM)	-AU$11.46m
Revenue (TTM)	AU$2.20m

7.4x

P/S Ratio

-1.4x

P/E Ratio

Is EMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EMD income statement (TTM)
Revenue	AU$2.20m
Cost of Revenue	AU$2.37m
Gross Profit	-AU$167.55k
Other Expenses	AU$11.29m
Earnings	-AU$11.46m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.028
Gross Margin	-7.61%
Net Profit Margin	-520.07%
Debt/Equity Ratio	33.5%

How did EMD perform over the long term?

See historical performance and comparison

EMD Stock Overview

Risk Analysis

Emyria Limited Competitors

ASX:EOF

AU$15.4m

ASX:IVX

AU$14.3m

ASX:NYR

AU$21.0m

ASX:AGH

AU$19.3m

Price History & Performance

Recent News & Updates

New major risk - Share price stability

Emyria Limited, Annual General Meeting, Nov 12, 2024

Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023)

New minor risk - Share price stability

New major risk - Market cap size

Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million.

Recent updates

New major risk - Share price stability

Emyria Limited, Annual General Meeting, Nov 12, 2024

Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023)

New minor risk - Share price stability

New major risk - Market cap size

Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million.

New major risk - Financial position

Emyria Limited Appoints Greg Hutchinson as Director

Emyria Limited Announces Board Changes

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.678228 million.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)

Emyria Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Emyria Limited Announces Strategic Board Transition

New minor risk - Share price stability

Emyria Limited (ASX:EMD) signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million.

Emyria Limited Secures Clinical-Grade MDMA Supply for Aust Patients

Emyria Limited Expands MDMA Programs Following Landmark TGA Decision

Emyria Limited Announces Commencement of First Dosing for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Its Acceptance into the Preclinical Screening Platform for Pain Program

Less than half of directors are independent

Emyria Limited and The University of Western Australia Expands Unique MDMA

Emyria Expands Clinical Sites for EMD-RX5 Phase 3 Trial

Emyria Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021)

Emyria Limited Receives Ethics Approval for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Initiation of Human Cell-Line Preclinical Studies to Advance Its Mdma-Inspired Drug Discovery Partnership with the University of Western Australia

Emyria Limited Announces Positive Progress of its Preclinical MDMA Analogue Medicine Program

Emyria Limited Reports Positive Phase 1 Trial Data for EMD-RX5 Indicating Ideal Bioavailability, Safety and Tolerability Among 12 Healthy and Demographically Diverse Volunteer Subjects

Emyria Limited Receives Further Positive MDMA Analogue Screening Results

Less than half of directors are independent

Emyria Limited Announces EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial

Emyria Limited Commences Dosing for EMD-RX5 Phase 1 Human Clinical Trial

Emyria Limited Commences for the EMD-RX5 Clinical Development Program

Emyria Limited Ethics Approval Receives for EMD-RX5 Phase 1 Study

Emyria Limited Announces Substantial Expansion of Proprietary MDMA Analogue Library Being Created with the University of Western Australia

Emyria Limited Announces Phase 1 Clinical Trials to Commence for Its Leading Ultra-Pure CBD Drug Candidate, Referred to as EMD-RX5

Emyria Limited announced that it expects to receive AUD 5 million in funding from Tattarang Pty Ltd

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Limited Provides Novel Mdma Analogue Screening Program Advanced Update

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Executes Pure CBD Agreement with Altasciences to Accelerate FDA and TGA Cannabinoid Registration Programs

Emyria Advances EMD-004 Program Towards Registration

Emyria Limited and Mind Medicine Australia Launch MDMA-Assisted Therapy Program for PTSD

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020)

Emyria Limited Announces the Appointment of Dr. Karen Smith to Chair the Company's Strategic Advisory Board

New 90-day high: AU$0.23

Emyria Limited Wins Digital Health Monitoring Grant with UWA

Emyria Limited Appoints Dr Richard Magtengaard, to Its Medical Advisory Board

Emyria Limited to Pursue Registration of EMD-003 with Australia's Therapeutic Goods Administration in 2021

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.

Emyria Limited Launches Drug Development Program Based on RWE

Emyria Limited Partners with Mind Medicine Australia

Executive Chairman recently bought AU$61k worth of stock

Emyria Limited Enters Data Deal with Zelira to Support Autism Trial

Zelira Therapeutics Ltd Enters into Agreement with Emyria Ltd

Emerald Clinics Limited to Report Fiscal Year 2020 Results on Oct 30, 2020

Shareholder Returns